See more : Graines Voltz S.A. (GRVO.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Relevium Technologies Inc. (RLLVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relevium Technologies Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Hiroshima Electric Railway Co.,Ltd. (9033.T) Income Statement Analysis – Financial Results
- Advance Metering Technology Limited (AMTL.BO) Income Statement Analysis – Financial Results
- Bridgetown Holdings Limited (BTWNU) Income Statement Analysis – Financial Results
- Danske Invest Fjernøsten Indeks (DKIFJIX.CO) Income Statement Analysis – Financial Results
- Cara Therapeutics, Inc. (0HTC.L) Income Statement Analysis – Financial Results
Relevium Technologies Inc. (RLLVF)
About Relevium Technologies Inc.
Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand name; and skin care products under the Push & Pull System brand. It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. Relevium Technologies Inc. is headquartered in Montreal, Canada.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 913.64K | 2.97M |
| Cost of Revenue | 499.17K | 1.78M |
| Gross Profit | 414.48K | 1.19M |
| Gross Profit Ratio | 45.37% | 40.15% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 1.31M | 2.31M |
| Selling & Marketing | 577.81K | 1.65M |
| SG&A | 1.89M | 3.96M |
| Other Expenses | -1.47M | 0.00 |
| Operating Expenses | 414.48K | 1.19M |
| Cost & Expenses | 913.64K | 2.97M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 750.88K | 566.68K |
| Depreciation & Amortization | 4.66K | 3.42K |
| EBITDA | -4.61M | -4.67M |
| EBITDA Ratio | -504.88% | -157.01% |
| Operating Income | -1.48M | -2.77M |
| Operating Income Ratio | -161.49% | -93.19% |
| Total Other Income/Expenses | -3.89M | -4.16M |
| Income Before Tax | -5.37M | -6.93M |
| Income Before Tax Ratio | -587.57% | -233.06% |
| Income Tax Expense | 0.00 | 0.00 |
| Net Income | -5.37M | -6.93M |
| Net Income Ratio | -587.57% | -233.06% |
| EPS | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 |
Relevium Technologies Completes Shares-For-Debt Transactions
Relevium Obtains Conditional TSXV Approval for the Settlement of the Outstanding Notes in Shares
Relevium Announces Settlement of the Outstanding Notes
Relevium Announces Shareholder Townhall and Conference Call
Relevium Announces Maturity of the Outstanding Convertible Debenture Notes and Begins Negotiations With Debenture Holders
Relevium Announces the Appointment of Dr. Wolfgang Renz as Chief Scientific Officer for Biocannabix Health Corporation
Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves
Biocannabix Enters Into LOI With IAM Health GmbH
Relevium Secures North American Exclusivity for Medical Examination Gloves, with First Shipment to Arrive in Los Angeles by Mid April
Relevium Announces Investor Relations Conference Call
Source: https://incomestatements.info
Category: Stock Reports